"Cloud" Collaboration Success: China's Gateway to the Future of Life Sciences Fully Opens to Australia

On July 24, the Australia Innovation MedTech Bootcamp, jointly organized by Wuxi International Life Science Innovation Park (I·Campus), the Australian Government, industry institutions, and AstraZeneca, successfully concluded.

A five-day “cloud” engagement, featuring 16 industry leaders delivering nearly 30 hours of comprehensive insights into the Chinese market, provided all-around guidance for the future “China journey” of the 13 selected top Australian innovative enterprises.

• ^{Powered by Austrade, the Landing Pad program, AstraZeneca, I∙Campus, and CSIRO}

• ^{5 Days, Nearly 30 Hours of High-Density Output}

• ^{16 Industry Leaders Deliver a Comprehensive Analysis of the Chinese Market}

• ^{Topics cover all aspects of the healthcare industry, including macro-level development, policy orientation, clinical research, capital financing, commercial operations, talent, and laws and regulations.}

• ^{13 Australian Innovative Medical Companies Gather Online in the “Cloud”}

• ^{Nearly 100 guests participated in the online “cloud” roadshow event}

A series of lectures delivered by cross-disciplinary experts explored specialized topics such as local regulations, clinical pathways, intellectual property protection, product approval and registration, and capital financing. Let us now review these presentations in the order they were delivered:

Li Dan Dane Richmond

Australian Consulate-General in Shanghai, Consul for Commerce

Australia boasts world-leading technology, innovation, highly skilled professionals, advanced research and development, and a robust healthcare system. However, it is not easy for foreign enterprises to enter the Chinese market. The Australian Landing Pad serves as a bridge for cooperation and communication between Chinese and Australian enterprises, providing assistance to Australian startups and growth-stage companies in entering the Chinese market.

Xu Jing

Vice President, AstraZeneca China; Head of Digital & Commercial Innovation

AstraZeneca is committed to transforming from a traditional pharmaceutical supplier into an innovative platform enterprise that provides whole-disease-management solutions for patients. Leveraging its resources and expertise in commercial operations, AstraZeneca will help life science innovators in Australia and around the world efficiently connect with the Chinese market through the I·Campus platform.

Sun Yan

Deputy Director, Wuxi High-Tech Zone Investment Promotion and Development Center

Wuxi is not only one of Forbes’ Best Cities for Business in China but also a major hub for the country’s Internet of Things (IoT) industry. In recent years, it has been committed to becoming a leading national demonstration city for the digital economy and promoting the development of intelligent innovation industries. I·Campus, jointly established by the Wuxi Municipal Government, the High-Tech Zone Administration, and AstraZeneca, was founded with integrated policy support, capital investment, and industry resources, and remains dedicated to providing comprehensive, closed-loop services to resident enterprises.

Chen Kai

Director, AstraZeneca China International Life Sciences Innovation Park

Amid this year’s pandemic landscape, I·Campus has continued to grow at a rapid pace, helping overseas enterprises enter the Chinese market and achieve milestone progress. This Australia-focused Innovation Camp will help medical innovation companies aspiring to enter the Chinese market get off to a fast start. We are confident that the platform built through government-enterprise collaboration will provide comprehensive support for the incubation and implementation of projects in the Chinese market.

Bai Tianwei Tim White

Australian Consulate-General in Chengdu, Consul (Commercial)

To address the growing burden of chronic diseases, the challenges of an aging society, and an overburdened hospital system, China is undertaking significant reforms in its healthcare sector. The country is committed to enhancing workforce and technological capabilities and rapidly integrating digital technologies across all areas of healthcare delivery.

Monique Donaldson

Business Australia Entrepreneur’s Program， Growth Facilitator

Achieving export success is no accident; it is built on designing the right international growth strategy for a company and continuously and deliberately strengthening its capabilities and resilience. Exporting products does not equate to international business expansion. When formulating an international expansion strategy, it is crucial to understand the import and export trade policies of each target market.

Charlotte Trinh 

IP Australia ；IP Counsellor to China

Intellectual property protection in the Chinese market is far better than outsiders imagine. However, it is undeniable that overseas enterprises must still do their due diligence before entering China, formulate IP strategies tailored to the Chinese market at an early stage, and make full use of the effective tools provided by China’s IP system. 

Shao Wenbin Eric Shao

Vice President, IQVIA; General Manager, Commercial Solutions, Greater China

The impact of the COVID-19 outbreak on China’s healthcare industry is evident. Meanwhile, the pandemic has served as a positive catalyst in many areas, such as increased government investment in primary healthcare infrastructure and the rise of online consultation models, which are poised to enter a period of accelerated growth.

Huang Xiao

Yunfeng Capital, Executive Director

China’s healthcare market has transitioned from the 1.0 stage, which focused on accessibility, to the 2.0 era, which balances affordability with quality of care. Demographic shifts associated with an aging population and changes in disease patterns, coupled with rising per capita GDP, have further stimulated robust demand on the demand side of the medical innovation market. This has given rise to a cohort of domestic innovative pharmaceutical companies, strengthened their ties with overseas counterparts, and facilitated the international expansion of Chinese enterprises. AstraZeneca’s I·Campus platform effectively connects domestic and international institutions and businesses. It is believed that such collaboration will foster a new generation of pioneering pharmaceutical innovation companies within the broader context of value-based healthcare.

Andrew Yu

Deloitte Consulting Partner, Head of Life Sciences & Healthcare

China’s healthcare market is expanding rapidly, yet a vast amount of patient demand remains unmet. This rapid growth has attracted numerous players to the healthcare sector. Overall, China’s healthcare market is evolving toward greater innovation, integration, and efficiency, and is currently at a critical juncture of transformation. Overseas companies entering the Chinese market must pay close attention to these market dynamics.

Peng Yifei

Vice President of Tigermed, General Manager of Tigermed Jietong

As an incubated partner of I·Campus, we will provide comprehensive professional guidance—spanning regulatory approval, clinical trials, product policy, regulatory affairs, marketing, and academic activities—to facilitate the entry of innovative medical devices from Australia and around the world into the Chinese market, ensuring their success at every stage.

Guo Rongrong

CICC Investment Banking – Executive Head, Healthcare & Pharmaceuticals

From a medium- to long-term perspective, the overall positive trend of China’s pharmaceutical industry remains unchanged. We are highly confident in the application of medical innovations, such as the adoption of AI technologies and the advancement of artificial intelligence. In the future, dual listings both domestically and offshore will become the norm.

Zhang Zhuolei

Global Partner and Chief Operating Officer, Greater China, Aon Hewitt

The war for talent across industries continues to intensify, a trend that is particularly pronounced in the medical innovation sector, which demands high levels of technical expertise. For innovative enterprises newly entering the Chinese market, formulating an effective talent development strategy is critical—not only to retain existing talent but also to attract fresh capabilities.

Zhou Lei

Partner, Global Law Offices

Even against the backdrop of the global COVID-19 pandemic, we believe that China’s healthcare industry will continue to develop, particularly in areas such as innovative drugs, healthcare digitalization, diagnostics, and internet-based healthcare. As a sector that has been subject to stringent regulation and ongoing systemic reforms in recent years, in-depth understanding of local legal practices and forward-looking assessment of policy trends are critical factors for foreign enterprises to achieve business success in China.

By constructingOpenness, Collaboration, and GlobalizationI·Campus is committed to providing a one-stop innovation empowerment platform for innovative enterprises at home and abroad, offering services in project implementation, innovation incubation, business acceleration, and scaling up, while also providing comprehensive support for companies to deepen their presence in the Chinese market and connect with global markets.

In the future, I·Campus will continue to leverage its platform advantages, gather premium resources from both domestic and international markets, and provide a broad and professional exchange platform for life sciences enterprises.

Wuxi International Life Science Innovation Park (I·Campus) is a life science innovation incubation platform jointly established by the Wuxi Municipal Government, Wuxi High-Tech Zone, and AstraZeneca, a global biopharmaceutical company. It was first announced at the Boao Forum for Asia in March 2019. With a planned area of approximately 300,000 square meters for its core R&D zone, the park builds an open innovation ecosystem to provide domestic and overseas innovative enterprises with a one-stop innovation empowerment platform covering project implementation, innovation incubation, commercial acceleration, and scale-up. Supported by government, industry, academia, research institutions, healthcare providers, and investors, Wuxi International Life Science Innovation Park is committed to becoming the preferred destination for global life science innovators to deepen their presence in the Chinese market and connect with the global market, pooling global wisdom to support Healthy China and realize international aspirations.

AstraZeneca is a science-led global biopharmaceutical company dedicated to the research, development, manufacturing, and marketing of prescription medicines, with a primary focus on three major therapeutic areas: oncology; cardiovascular, renal, and metabolism; and respiratory diseases. Headquartered in Cambridge, United Kingdom, AstraZeneca operates in more than 100 countries, and its innovative medicines benefit millions of patients worldwide. For more information, please visitwww.astrazeneca.com 。

The Australian Trade and Investment Commission (Austrade) is an Australian government agency responsible for promoting trade, investment, and education, formulating relevant tourism policies, and conducting research projects.

The Australian Trade and Investment Commission assists businesses worldwide in seeking investment opportunities in Australia and procuring Australian products and services.

Services provided by the Australian Trade and Investment Commission include:

▪ Provide information on the competitive advantages of Australia’s industries

▪ Assist enterprises in identifying potential investment opportunities and strategic partners

▪ Assist enterprises in identifying Australian suppliers

Austrade operates nine offices across Greater China, including in Beijing, Shenyang, Shanghai, Wuhan, Chengdu, Guangzhou, Shenzhen, Taipei, and Hong Kong. For more information, please visit the Australian Trade and Investment Commission website.Official Website 。

In December 2015, the Australian Federal Government announced the launch of the “National Innovation and Science Agenda,” under which AUD 36 million would be specifically invested to implement the “Global Innovation Strategy” in support of taking Australian innovation and entrepreneurship global. The “Landing Pads” program is the most critical component of the Global Innovation Strategy, aiming to support Australian-started startups that are market-ready in expanding globally. Funded by the federal government, the Australian Landing Pads program has established landing pads in five major global innovation hubs: San Francisco (USA), Tel Aviv (Israel), Shanghai (China), Berlin (Germany), and Singapore.